YTHDF2 promotes intrahepatic cholangiocarcinoma progression and desensitises cisplatin treatment by increasing CDKN1B mRNA degradation

BACKGROUND: Intrahepatic cholangiocarcinoma (ICC) is an aggressive cancer with exceedingly poor prognosis, and chemoresistance is a huge challenge for treatment. N6‐methyladenosine (m(6)A) modification plays an important role in the progression and chemoresistance of cancers. We aimed to investigate...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Chen‐Song, Zhu, Ying‐Qin, Xu, Qiong‐Cong, Chen, Siyun, Huang, Yue, Zhao, Guangyin, Ni, Xuhao, Liu, Bo, Zhao, Wei, Yin, Xiao‐Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9191870/
https://www.ncbi.nlm.nih.gov/pubmed/35696608
http://dx.doi.org/10.1002/ctm2.848

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9191870/
https://www.ncbi.nlm.nih.gov/pubmed/35696608
http://dx.doi.org/10.1002/ctm2.848

Ejemplares similares